A group of 227 cases of non-Hodgkin's lymphoma included seven favorable and four unfavorable histologic classes with collective median survival times of 83 and 16 months, respectively. The favorable group included three follicular subgroups (cleaved, mixed, and large noncleaved) and four diffuse cla
Incidence and mortality from non-Hodgkin lymphoma in Europe: The end of an epidemic?
β Scribed by Cristina Bosetti; Fabio Levi; Jacques Ferlay; Franca Lucchini; Eva Negri; Carlo La Vecchia
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- French
- Weight
- 353 KB
- Volume
- 123
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
NonβHodgkin lymphomas (NHL) are among the few neoplasms whose incidence and mortality have been rising in Europe and North America over the last few decades. To update trends from NHL, we considered mortality data up to 2004 in several European countries, and for comparative purpose in the USA and Japan. We also analyzed patterns in incidence for selected European countries providing national data. In most European countries, NHL mortality rose up to the mid 1990s, and started to level off or decline in the following decade. The rates were, however, still increasing in eastern Europe. Overall, in the European Union, mortality from NHL declined from 4.3/100,000 to 4.1 in men and from 2.7 to 2.5 in women between the late 1990s and the early 2000s. Similarly, NHL mortality rates declined from 6.5/100,000 to 5.5 in US men and from 4.2 to 3.5 in US women. In most countries considered, NHL incidence rates rose up to 1995β99, while they tended to level off or decline thereafter, with particular favorable patterns in countries from northern Europe. Thus, the epidemic of NHL observed during the second half of the 20th century has now started to level off in Europe as in other developed areas of the world. Β© 2008 WileyβLiss, Inc.
π SIMILAR VOLUMES
## Background: The precise incidence of familial hodgkin disease (hd) and non-hodgkin lymphoma (nhl) in first-degree relatives is unknown. through record linkage using two population-based sources, the authors estimated the risk of hd and nhl in family members of lymphoma probands. ## Methods: Th
## Background: Chemotherapy containing anthracycline is the standard initial treatment for aggressive non-hodgkin's lymphoma (nhl), and the international prognostic index (ipi) is widely accepted as the standard tool for determining the prognosis of patients with this disease. however, the data on